An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)
- PMID:9150318
An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)
Erratum in
- Eur Respir J 1997 Jul;10(7):1696
Abstract
The objectives of this study were to compare the efficacy and safety of salmeterol xinafoate (50 and 100 microg b.i.d.) with that of placebo, when added to existing therapy, in the treatment of patients with chronic obstructive pulmonary disease (COPD). Six hundred and seventy four patients were randomized to receive either salmeterol 50 microg b.i.d., salmeterol 100 microg b.i.d., or placebo treatment for a period of 16 weeks. The results showed a significant improvement in daily symptom scores noted for patients taking either 50 microg (p=0.043) or 100 microg b.i.d. salmeterol (p=0.01) compared with placebo, with a corresponding decrease in additional daytime salbutamol requirements for both salmeterol groups. The same pattern was reflected for night-time symptoms and additional salbutamol use. During treatment, forced expiratory volume in one second (FEV1) measurements improved significantly in each salmeterol group, with up to a 7% improvement observed at the end of the study. Although no difference was observed between treatment groups for the distance walked in 6 min, patients treated with salmeterol 50 microg b.i.d. were significantly less breathless than those treated with placebo after their 6 min walk, after 8 weeks (p=0.024) and 16 weeks (p=0.004) of therapy. Adverse events were similar in all three groups except for tremor, which was significantly higher in the 100 microg b.i.d. salmeterol group (p=0.005) compared both with 50 microg b.i.d. salmeterol and placebo. Salmeterol offered further positive improvement to the effect of therapy in patients with chronic obstructive pulmonary disease when added to their existing regimens. This clinical improvement was similar both with 50 and 100 microg b.i.d. dosage, although the group receiving 50 microg b.i.d. tolerated the drug better than those receiving 100 microg b.i.d. salmeterol.
Similar articles
- A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.Broseghini C, Testi R, Polese G, Tosatto R, Rossi A.Broseghini C, et al.Pulm Pharmacol Ther. 2005;18(2):103-8. doi: 10.1016/j.pupt.2004.10.006. Epub 2005 Jan 7.Pulm Pharmacol Ther. 2005.PMID:15649852Clinical Trial.
- Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.Boyd G.Boyd G.Eur Respir J. 1995 Sep;8(9):1494-8.Eur Respir J. 1995.PMID:8575574Clinical Trial.
- [The effect of salmeterol in the treatment of smokers with chronic obstructive lung disease].Ulrik CS.Ulrik CS.Ugeskr Laeger. 1996 Jun 17;158(25):3604-7.Ugeskr Laeger. 1996.PMID:8693619Clinical Trial.Danish.
- Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.Jarvis B, Markham A.Jarvis B, et al.Drugs Aging. 2001;18(6):441-72. doi: 10.2165/00002512-200118060-00006.Drugs Aging. 2001.PMID:11419918Review.
- Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.Stockley RA, Whitehead PJ, Williams MK.Stockley RA, et al.Respir Res. 2006 Dec 29;7(1):147. doi: 10.1186/1465-9921-7-147.Respir Res. 2006.PMID:17196106Free PMC article.Review.
Cited by
- Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.Spencer S, Karner C, Cates CJ, Evans DJ.Spencer S, et al.Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD007033. doi: 10.1002/14651858.CD007033.pub3.Cochrane Database Syst Rev. 2011.PMID:22161409Free PMC article.Review.
- Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G.Westwood M, et al.Respir Res. 2011 Apr 8;12(1):40. doi: 10.1186/1465-9921-12-40.Respir Res. 2011.PMID:21477298Free PMC article.Review.
- Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing.Gupta P, O'Mahony MS.Gupta P, et al.Drugs Aging. 2008;25(5):415-43. doi: 10.2165/00002512-200825050-00005.Drugs Aging. 2008.PMID:18447405Review.
- Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, Buckley F, Ellis A, Jones P.Cope S, et al.Respir Res. 2013 Oct 7;14(1):100. doi: 10.1186/1465-9921-14-100.Respir Res. 2013.PMID:24093477Free PMC article.
- Theoretical models for the simulation of particle deposition and tracheobronchial clearance in lungs of patients with chronic bronchitis.Sturm R.Sturm R.Ann Transl Med. 2013 Apr;1(1):3. doi: 10.3978/j.issn.2305-5839.2012.11.02.Ann Transl Med. 2013.PMID:25332949Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources